Strong international acceptance of its Series 9600 mobile C-armhas helped OEC Medical Systems record sharply higher revenuesand profits for its second quarter (end-June). The Salt Lake Citycompany had second-quarter revenues of $26.1 million, up 34%
Strong international acceptance of its Series 9600 mobile C-armhas helped OEC Medical Systems record sharply higher revenuesand profits for its second quarter (end-June). The Salt Lake Citycompany had second-quarter revenues of $26.1 million, up 34% overthe $19.4 million in product sales in the same period last year.Net income was $2.8 million, compared to $300,000 in the secondquarter of 1994.
OEC was bedeviled by delays in shipping Series 9600 last yearthat were reflected in the company's 1994 results, but those bugshave been worked out, according to chairman, president and CEORuediger Naumann-Etienne. OEC's numbers this year were aided bystrong international demand for the product. International salesfor the first six months of 1995 have already exceeded the totalrecorded last year, he said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.